Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Axon guidance | R-HSA-422475 | map04360 | nisoxetine | 4500 | drug-path |
| Asthma | R-HSA-444620 | map05310 | nisoxetine | 4500 | drug-path |
| Allograft rejection | R-HSA-9679028 | map05330 | nisoxetine | 4500 | drug-path |
| Colorectal cancer | R-HSA-4791275 | map05210 | nisoxetine | 4500 | drug-path |
| Type I diabetes mellitus | R-HSA-5683209 | map04940 | nisoxetine | 4500 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | nisoxetine | 4500 | drug-path |
| Huntington's disease | R-HSA-1643685 | 0 | nisoxetine | 4500 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | bufexamac | 2466 | drug-path |
| Cell adhesion molecules (CAMs) | R-HSA-1031690 | 0 | bufexamac | 2466 | drug-path |
| Type II diabetes mellitus | R-HSA-2127377 | map04930 | bufexamac | 2466 | drug-path |
| Graft-versus-host disease | R-HSA-1643685 | map05332 | bufexamac | 2466 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | bufexamac | 2466 | drug-path |
| Shigellosis | 0 | map05131 | bufexamac | 2466 | drug-path |
| Pathogenic Escherichia coli infection | R-HSA-9609646 | map05130 | bufexamac | 2466 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | bufexamac | 2466 | drug-path |
| Asthma | R-HSA-444620 | map05310 | bufexamac | 2466 | drug-path |
| RNA polymerase | R-HSA-73864 | map03020 | bufexamac | 2466 | drug-path |
| Calcium signaling pathway | R-HSA-381753 | map04020 | bufexamac | 2466 | drug-path |
| Allograft rejection | R-HSA-9679028 | map05330 | bufexamac | 2466 | drug-path |
| Type I diabetes mellitus | R-HSA-5683209 | map04940 | bufexamac | 2466 | drug-path |